Revance Therapeutics, Inc. RVNC

Filed with the SEC on Feb 6, 2025. Reported event date Feb 6, 2025.

Items reported in this filing

Item 1.01 Entry into a Material Definitive Agreement
Item 2.01 Completion of Acquisition or Disposition of Assets
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
An exchange told the company it does not meet a continued-listing rule, or the company is delisting or moving its listing: Form 8-K Item 3.01. Many of these are compliance notices with time to fix, not closures.
Item 3.03 Material Modification to Rights of Security Holders
Item 5.01 Changes in Control of Registrant
Item 5.02 Departure or Appointment of Directors or Officers; Compensatory Arrangements
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01 Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits

Wire Pass $1.95/month or $19.50/year lets you watch up to 100 companies like this one. Free during preview See pricing